ABSTRACT The hepatitis B virus (HBV) vaccination schedule in Libya follows international recommendations (1st dose at birth, 2nd after 1 month and 3rd after 6 months). This research aimed to evaluate the long-term protection of the HBV immunization programme in Tripoli and to determine the best age to administer booster doses. Serum levels of hepatitis B surface antigen were determined in 277 randomly selected children aged 1-12 years. The response to HBV vaccine in 1-3-year-olds was 93.2%, but this declined with age and at 7-9 years after initial vaccination only 53.1% of children had protective titres (≥ 10 mIU/mL). No significant differences between males and females in antibody persistence or response to vaccine were observed. We recommend continuing the HBV vaccination programme and that a booster dose be given to 6-year-old children to ensure maximum protection during the period of school entry and beyond.
Introduction
Approximately 2 billion people, about 33% of the world population, are infected by hepatitis B virus (HBV). Over 300 million among them are chronically infected, which represents about 5% of the population, and about a quarter of them suffers from the serious consequences of liver diseases such as chronic hepatitis, primary hepatocellular carcinoma and cirrhosis [1] . HBV kills 1-2 million people every year [2] . The hepatitis B surface antigen (HBsAg) carrier rate varies from less than 1% in Europe to 20% in sub-Saharan Africa.
The prevalence of disease among Libyans was 2.18% and 2.20% in 2004 and 2005 respectively [3] . Libya is considered an area of intermediate endemicity for HBV infection, and the frequency of HBV is lower among immunized people. The number of HBsAg carriers in Libya is estimated between 120 000 and 150 000, and the infections have occurred mostly among high-risk behaviour people: those with a history of scarification (29.0%), contact with hepatitis B patients (22.8%), history of jaundice (19.0%), family history of hepatitis B (10.7%), history of blood transfusion (9.0%) and multiple sexual partners (7.2%) [4] . However, the exact number of infected people is not known, and therefore many people receive no counselling or treatment or even testing [4] .
Despite the World Health Organization (WHO) recommendation to all countries to start HBV vaccination by 1997 [5] suggestions: 1st dose given at birth, the 2nd after 1 month and the 3rd after 6 months. The duration of protection provided by the vaccine in Libya is unknown and this study was carried out in order to evaluate the long-term protection of hepatitis B vaccine and the need for booster doses.
Methods

Sample
The study was performed on 277 randomly selected children (156 boys and 125 girls) aged 1-12 years from different areas of Tripoli. This is the capital city of Libya and different Libyan subgroups are represented in the population. All children received 3 doses of recombinant hepatitis B vaccine at the birth, after 1 month and after 6 months.
Ethical approval was obtained from the Academy of Graduate Studies in Tripoli. All the samples were obtained after informed consent had been given; as patients were under age, approval was obtained from parents.
Data collection
Samples were collected from children in Alkadesia medical centre and Algla hospital in Tripoli between February and July 2009; 3 mL of venous blood was taken by venepuncture into heparinized tubes.
Anti-HBsAg quantification was performed at Al-Mubdeoun laboratory in Tripoli in October 2009. The sera were separated after clotting using centrifugation. Serum samples were stored at -20 °C until analyses were performed. Serological analyses were performed using bioMérieux mini VIDAS® automated immunoassay chemistry system. BioMérieux VIDAS hepatitis B surface antibody (anti-HBs) total quick kit was used for the HBV antibody identification following the manufacturer's instruction. This assay combines an enzyme immunoassay sandwich method with a final fluorescent detection using the enzyme linked fluorescent assay technique.
Analysis
The children were analysed in 4 groups according to age: 1-3 years (88 children), 4-6 years (98 children), 7-9 years (49 children) and 10-12 years (42 children). Statistical analyses were performed using the software SPSS, version 17.0.
Results
The results collected from the 277 children screened for anti-HBs showed that 89 had anti-HBs antibody < 10 mIU/ mL, which is considered non-protective and 188 children showed a titre ≥ 10 mIU/mL, which is considered protective. Of the 88 children aged 1-3 years who received the 3 doses of vaccine 6 (6.8%) did not show a positive response to the vaccination (Table 1 ) and 93.2% showed a positive response. At age 4-6 years 73.3% responded, at age 7-9 years 60.0% and by age 10-12 years only 25.0% had a positive response (Table  1) . Figure 1 shows that the response to vaccine (i.e. the percentage of children with a titre ≥ 10 mIU/mL) and the anti-HBs titre declined linearly with age across the 4 age groups, from the highest response at ages 1-3 years to lowest at 10-12 years.
No significant differences were observed in the titre values between males and females, either in the response to vaccine or in the decrease of antibody titres across age groups (P = 0.817 and P = 0.386 respectively) ( Table 1) .
Discussion
This study in Libya showed that only 6.8% of the 1-3-year-old cohort who received the 3 doses of vaccine did not respond positively to the vaccination. This result is slightly higher compared with the findings of other studies performed in Taiwan, Turkey, The Gambia and Palestine (Gaza) that show percentages of non-responders of 3.3%, 2.3%, 5% and 5.5% respectively [6] [7] [8] . Further studies in the future will be needed to identify the reason for lower immune responses (pathology, ethnicity, family history, etc.). The total positive response to hepatitis B vaccine among infants (93.2%) confirmed a good vaccination coverage in Libya. This is in agreement with Egyptian data, which revealed a response rate of 93.3% 1 month after vaccination [9] , and with data reported by the Ministry of Health in New Zealand [10] and Desombere et al. in Belgium [11] , indicating a positive response in children varying from 90% to 95%.
Different factors can affect the responsiveness to hepatitis B vaccine [12] . In general, variations in immune response among individuals, the age of the vaccine, differences in manufacturing and the timing of the 3rd vaccine dose administration are considered the main factors that can affect the response to vaccination [13] . Hadler et al. found that response to vaccination was improved with increasing age but also that the response was improved by increasing the time between doses to more than 7 months [14] . In contrast to this observation, Inskip et al. reported that the only additional factor which contributed to the response was the logarithm of the length of time between the first and the second dose of vaccine, with a longer interval resulting in a lower antibody level. So when there was a doubling of the interval between the first and second dose from 4 to 8 weeks the reduction in antibody level was approximately 12% [15] .
Age-group analysis showed that the response to vaccine and the anti-HBs titre declined across the 4 age group cohorts, indicating a decrease in vaccine efficacy against infection with time. The titre decline observed in this study disagrees with a study from The Gambia, which is considered an HBV endemic country, that concluded that vaccination early in life can provide long-lasting efficacy [15] . In contrast, our findings are in agreement with the results of the vaccination of Iranian children, which is an intermediate prevalence country [1] . Research carried out in Egypt showed a faster rate in the waning of the titre than our finding: 5 years after vaccination the anti-HBs titre was 53.3% [9] . In addition, a study performed in Senegal showed that the titre fell to < 10 mIU/ mL in 33% of children during the 5th and 6th years of life and the authors recommended the introduction of a booster 4th dose after 5 years in order to maximize the vaccination effect [16] . In general, the findings of previous studies suggest that the efficacy of hepatitis B vaccine is variable depending on the country. This situation could be attributed to many reasons including: prevalence of hepatitis B disease, differences in immune response, endemicity, vaccination coverage, timing of vaccination, vaccination schedule, differences in vaccine synthesis, poor vaccine cold-chain storage and variations in the methods used to assay antibody titre [13] .
Analyses carried out in Palestine, Alaska and The Gambia, which are considered highly endemic areas for HBV carriers, show a "long term"' persistence of antibody as compared with other studies performed in the Islamic Republic of Iran, Egypt and Libya (this study), which are considered areas of intermediate HBV endemicity, and which showed a faster rate of antibodies decline. The immunization schedule might also play a role in determining anti-HBs levels and the time interval between doses appears to affect antibody levels [17] . Concerning this point, our results are in agreement with the findings of a study done in Egypt, in which a 2-, 4-and 6-month hepatitis B vaccine schedule has been adopted, despite researchers recommending a new vaccination schedule at 1, 2 and 9 months, to extend the persistence of antibody [18] . The 2 most-used schedules for the hepatitis B vaccine are 1, 2 and 12 months and 0, 1 and 6 months [17] . Da Villa et al. found that a higher level of protective anti-HBs was achieved when the vaccine dose was administered to 3-month-old children instead of 1-month-old infants [19] , while Williams et al. suggested that the persistence of protection for a longer period takes place when the first vaccine dose is administered soon after birth [20] . The type of vaccine (plasma or yeastderived) also plays an important role in the response to vaccination and the persistence of its effects. Da Villa et al. found that the DNA recombinant vaccine has a higher titre level (97.6%) as compared with plasma-derived vaccine (80.4%). In addition, Floreani et al. found a slightly higher titre with plasma-derived vaccine than yeastderived vaccine (87.8% and 81.6% respectively) [21] . Zuckerman et al. suggested that an elevate vaccine dosage may lead to the production of high levels of anti-HBs [22] .
Some studies suggested that by beginning the first vaccination dose at a later age the persistence of anti-HBs might be improved as the prevalence of anti-HBs titre ≥ 10 mIU/mL ranged from 79% to 85% at 10-12 years of age [23, 24] . In addition, Petersen et al. found that antibody levels decreased most in individuals who received the vaccine before the age of 4 years [25] . These authors studied the results obtained after vaccination had been given at 2-3 months of age or later and showed a slower rate of decline of the titre compared with our study in which children received the 1st dose within the 1st weeks of life, as recommended by ACIP [25] .
Research in the Islamic Republic of Iran showed that 60.9% of healthcare workers had anti-HBs titre ≥ 10 mIU/mL 10 years after vaccination [26] . Furthermore, in the USA 47 out of 54 health professionals (87%) showed anti-HBs response to anti-HBs > 10 S/N RIA units 10 years after vaccination [27] .
No significant sex differences were observed in our study in the response to vaccine or in the decrease of antibody titres across age groups. This finding is in agreement with other studies, indicating that in HBV vaccination programmes sex is not a variable that has to be considered in order to evaluate the efficacy of the campaign [1, [6] [7] [8] 15] .
Conclusions
This study showed a decreasing immunogenicity associated with increased age. Although 70.4% of the vaccinated children aged 4-6 years old were protected only half of the children (53.1%) who had been vaccinated from birth had anti-HBs levels ≤ 10 mIU/mL 7-9 years after the last dose of vaccine was administered. Hepatitis B vaccine is highly immunogenic and immunization with hepatitis B vaccine in Libya showed a high response in infants aged 1-3 years (93.2%), which is likely to have a beneficial impact on HBV transmission in this age group. This study strongly suggests that continuation of the hepatitis B immunization programme would be beneficial in Libya, in line with findings from the available literature and the WHO recommendations that emphasize the importance of administering the 1st dose of the hepatitis B vaccine immediately after birth in order to avoid transmission of HBV during childhood.
The findings of this research have confirmed that the response to hepatitis B vaccine disappears over time. Therefore a booster dose might be necessary for children at least 6 years after the first vaccination to ensure maximum protection in the period of school entry and adulthood. This observation must be evaluated depending on the country, the endemicity of the disease and the condition and schedule of the immunization programme.
